Psychological symptoms during and after Austrian first lockdown in individuals with bipolar disorder? A follow-up control-group investigation.

Anxiety Bipolar disorder COVID-19 Depression Global symptom load Lockdown Somatization

Journal

International journal of bipolar disorders
ISSN: 2194-7511
Titre abrégé: Int J Bipolar Disord
Pays: Germany
ID NLM: 101622983

Informations de publication

Date de publication:
01 Jun 2021
Historique:
received: 23 11 2020
accepted: 24 02 2021
entrez: 1 6 2021
pubmed: 2 6 2021
medline: 2 6 2021
Statut: epublish

Résumé

The coronavirus disease (COVID-19) pandemic, a global health crisis, has resulted in widespread socioeconomic restrictions including lockdown, social distancing, and self-isolation. To date, little is known about the psychological impact of the COVID-19 pandemic and lockdown on patients with bipolar disorder as a particularly vulnerable group. An online survey was conducted in Austria at two points of measurement (T1 April 2020 during the first lockdown vs. T2 May 2020 at post-lockdown). The sample comprises 20 patients with bipolar disorder (mean age = 49.4 ± 15.6 years) and 20 healthy controls (mean age = 32.7 ± 9.6 years). A 2 × 2 factorial design to compare two time points (T1 vs. T2) and two groups (patients vs. healthy controls) was used. Main outcome measures included the Brief Symptom Inventory-18 (BSI-18) and a (non-validated and non-standardized) assessment to determine COVID-19 fears and emotional distress due to social distancing. Multiple linear regression analyses were used to assess the longitudinal association of COVID-19 fears/emotional distress due to social distancing during lockdown (T1) and psychological symptoms after lockdown (T2). At T1, results demonstrated higher scores in BSI-18 subscales depression, anxiety and global severity index as well as emotional distress due to social distancing in bipolar patients compared to controls. There was a significant time x group interaction in the BSI-18 subscale somatization showing a decreasing trend in patients with BD compared to controls. No time effects in BSI-18 subscales or COVID-19 fears/emotional distress due to social distancing were observed. Regression analyses showed that COVID-19 fears during lockdown predicted somatization, only in patients. There was a connection between the lockdown measures and somatization symptoms observed in patients. When the first steps of easing the social restrictions in May 2020 took place, somatization decreased only in the bipolar compared to the control group. Higher COVID-19 fears during lockdown predicted later symptoms at post-lockdown. Long-term impacts of the COVID-19 pandemic need further investigations to improve current therapeutic approaches and prevent fears and distress during lockdown in individuals with bipolar disorder in times of crisis.

Sections du résumé

BACKGROUND BACKGROUND
The coronavirus disease (COVID-19) pandemic, a global health crisis, has resulted in widespread socioeconomic restrictions including lockdown, social distancing, and self-isolation. To date, little is known about the psychological impact of the COVID-19 pandemic and lockdown on patients with bipolar disorder as a particularly vulnerable group.
METHODS METHODS
An online survey was conducted in Austria at two points of measurement (T1 April 2020 during the first lockdown vs. T2 May 2020 at post-lockdown). The sample comprises 20 patients with bipolar disorder (mean age = 49.4 ± 15.6 years) and 20 healthy controls (mean age = 32.7 ± 9.6 years). A 2 × 2 factorial design to compare two time points (T1 vs. T2) and two groups (patients vs. healthy controls) was used. Main outcome measures included the Brief Symptom Inventory-18 (BSI-18) and a (non-validated and non-standardized) assessment to determine COVID-19 fears and emotional distress due to social distancing. Multiple linear regression analyses were used to assess the longitudinal association of COVID-19 fears/emotional distress due to social distancing during lockdown (T1) and psychological symptoms after lockdown (T2).
RESULTS RESULTS
At T1, results demonstrated higher scores in BSI-18 subscales depression, anxiety and global severity index as well as emotional distress due to social distancing in bipolar patients compared to controls. There was a significant time x group interaction in the BSI-18 subscale somatization showing a decreasing trend in patients with BD compared to controls. No time effects in BSI-18 subscales or COVID-19 fears/emotional distress due to social distancing were observed. Regression analyses showed that COVID-19 fears during lockdown predicted somatization, only in patients.
CONCLUSIONS CONCLUSIONS
There was a connection between the lockdown measures and somatization symptoms observed in patients. When the first steps of easing the social restrictions in May 2020 took place, somatization decreased only in the bipolar compared to the control group. Higher COVID-19 fears during lockdown predicted later symptoms at post-lockdown. Long-term impacts of the COVID-19 pandemic need further investigations to improve current therapeutic approaches and prevent fears and distress during lockdown in individuals with bipolar disorder in times of crisis.

Identifiants

pubmed: 34059980
doi: 10.1186/s40345-021-00222-8
pii: 10.1186/s40345-021-00222-8
pmc: PMC8166528
doi:

Types de publication

Journal Article

Langues

eng

Pagination

16

Références

Am J Psychiatry. 2013 Mar;170(3):265-74
pubmed: 23361837
Psychol Med. 2021 Apr;51(6):1054-1056
pubmed: 32423496
Nervenarzt. 2007 Jun;78(6):651-6
pubmed: 16832698
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Brain Behav Immun. 2020 Jul;87:100-106
pubmed: 32353518
N Engl J Med. 2020 Aug 6;383(6):510-512
pubmed: 32283003
Lancet Psychiatry. 2020 Apr;7(4):e21
pubmed: 32199510
Psychiatry Res. 2020 Sep;291:113265
pubmed: 32763536
Front Psychiatry. 2020 May 11;11:410
pubmed: 32477186
J Clin Psychiatry. 2020 Apr 14;81(3):
pubmed: 32297718
Biol Psychiatry. 2012 Aug 15;72(4):303-10
pubmed: 22365631
Lancet Psychiatry. 2015 Aug;2(8):710-717
pubmed: 26249302
JAMA Psychiatry. 2020 Dec 1;77(12):1205-1206
pubmed: 32391857
QJM. 2020 Oct 1;113(10):707-712
pubmed: 32539153
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
PLoS One. 2020 Jun 25;15(6):e0235305
pubmed: 32584897
Asian J Psychiatr. 2020 Jun;51:101990
pubmed: 32163908
Psychiatr Q. 2020 Dec;91(4):1121-1133
pubmed: 32803472
Clin Psychol Rev. 2011 Apr;31(3):383-98
pubmed: 21334286
Psychiatry Res. 2020 Aug;290:113145
pubmed: 32544650
Lancet. 2016 Aug 27;388(10047):869-70
pubmed: 27597464
Psychol Med. 2000 Sep;30(5):1005-16
pubmed: 12027038
Curr Opin Psychiatry. 2007 Jul;20(4):406-16
pubmed: 17551358
Psychiatry Res. 2020 Jul;289:113098
pubmed: 32434092
Int J Geriatr Psychiatry. 2021 Jun;36(6):892-900
pubmed: 33368692
Neuropsychobiology. 2021;80(1):1-11
pubmed: 32454501
Front Psychiatry. 2020 Dec 03;11:580736
pubmed: 33343419
Psychiatr Serv. 2020 Nov 1;71(11):1188-1190
pubmed: 32878542
Global Health. 2020 Dec 18;16(1):119
pubmed: 33339523
J Affect Disord. 2018 Feb;227:681-687
pubmed: 29174742
Schizophr Res. 2020 Sep;223:192-198
pubmed: 32771308
J Med Virol. 2020 Oct;92(10):1962-1970
pubmed: 32314806
Int J Psychophysiol. 2020 Sep;155:99-104
pubmed: 32522512
Internet Interv. 2020 Apr;20:100317
pubmed: 32289019
Lancet Psychiatry. 2021 Feb;8(2):121-129
pubmed: 33306975
Asian J Psychiatr. 2020 Jun;51:102073
pubmed: 32278889
Front Psychiatry. 2020 Aug 07;11:790
pubmed: 32848952
Mil Med. 2020 Dec 30;:
pubmed: 33377975
J Affect Disord. 2021 Feb 15;281:13-23
pubmed: 33279864
Dtsch Med Wochenschr. 2020 May;145(10):675-681
pubmed: 32274787
Brain Behav Immun. 2020 Jul;87:99
pubmed: 32360604
J Abnorm Psychol. 2015 Feb;124(1):4-16
pubmed: 25688428
J Clin Psychiatry. 2010 Jan;71(1):66-72
pubmed: 19852904
J Affect Disord. 2020 Oct 1;275:69-77
pubmed: 32658826
BMC Med Res Methodol. 2017 Jan 26;17(1):14
pubmed: 28125960
Psychol Res Behav Manag. 2020 Sep 03;13:713-720
pubmed: 32982500
Asian J Psychiatr. 2020 Aug;52:102066
pubmed: 32302935
Transl Psychiatry. 2020 Aug 20;10(1):291
pubmed: 32820171
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):1-8
pubmed: 22613185
Ann Acad Med Singap. 2020 Jan;49(3):155-160
pubmed: 32200399
Int J Ment Health Addict. 2020 Jul 11;:1-13
pubmed: 32837442
J Affect Disord. 2005 Mar;85(1-2):153-68
pubmed: 15780686
COPD. 2018 Dec;15(6):612-620
pubmed: 30714418
Lancet Psychiatry. 2020 May;7(5):390
pubmed: 32353271
J Affect Disord. 2008 Apr;107(1-3):275-9
pubmed: 17884176
Biol Psychiatry. 1997 Nov 15;42(10):948-55
pubmed: 9359982
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
F1000Res. 2020 Feb 7;9:93
pubmed: 32518634
World Psychiatry. 2016 Jun;15(2):166-74
pubmed: 27265707
Telemed J E Health. 2020 Apr;26(4):377-379
pubmed: 32202977
Bipolar Disord. 2020 Sep;22(6):641-643
pubmed: 32511859
Bipolar Disord. 2019 May;21(3):270-275
pubmed: 30051555
J Pers. 2004 Dec;72(6):1365-93
pubmed: 15509286
J Affect Disord. 2016 Nov 01;204:205-13
pubmed: 27371906
Int J Bipolar Disord. 2020 May 20;8(1):21
pubmed: 32435920

Auteurs

Nina Dalkner (N)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Jolana Wagner-Skacel (J)

Department of Medical Psychology and Psychotherapy, Medical University of Graz, Auenbruggerplatz 3, 8036, Graz, Austria. jolana.wagner-skacel@medunigraz.at.

Michaela Ratzenhofer (M)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Frederike Fellendorf (F)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Melanie Lenger (M)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Alexander Maget (A)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Adelina Tmava-Berisha (A)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

René Pilz (R)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Robert Queissner (R)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Carlo Hamm (C)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Susanne Bengesser (S)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Martina Platzer (M)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Armin Birner (A)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Eva Reininghaus (E)

Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Auenbruggerplatz 31, Graz, 8036, Austria.

Classifications MeSH